Bayer Stock Torn Between Legal Turmoil and Pipeline Promise as Key Catalysts Loom

Bayer shares edge up as Roundup settlement faces objection, but Kerendia approvals and ASCO data boost pharma outlook; Q1 EPS beats estimates.

Bayer shares are holding near the €38.50 mark, caught between a robust operational performance and a legal firestorm that threatens to derail the company's long-awaited closure on its Roundup legacy. The stock has surged roughly 57% over the past twelve months, yet an annualized volatility of nearly 34% underscores the persistent uncertainty investors are pricing in.

Legal Challenge Threatens $675 Million Settlement Fee

The biggest near-term legal flashpoint centres on the proposed Roundup class-action settlement in Missouri. Last week, attorneys representing 13 cancer patients filed a formal objection with the Circuit Court of the City of St. Louis, asking the judge to reject the deal as unconstitutional. At the heart of the dispute is a $675 million fee pool for lead counsel, which the objecting lawyers argue comes at the expense of adequate compensation for individual plaintiffs. One day later, they moved to transfer the entire proceeding to a federal court, a maneuver that could push the final hearing—scheduled for July 9—well past its current date.

Bayer is pushing back. A Monsanto spokesperson characterised such objections as routine in settlements of this scale, adding that the company is working to keep the case in state court. Christopher Seeger, the plaintiffs' attorney who negotiated the accord, dismissed the transfer request as a baseless delay tactic. For CEO Bill Anderson, resolving the Roundup litigation is essential to restoring predictability to the group's planning.

Two Pharma Catalysts Brighten the Outlook

Against that legal storm, Bayer's pharmaceuticals division delivered a double dose of positive news on Monday. China's National Medical Products Administration approved Kerendia on May 22 for a new indication—heart failure with a left ventricular ejection fraction of at least 40%, covering mildly reduced and preserved ejection fraction. The drug was previously limited in China to chronic kidney disease in Type-2 diabetes. Separately, the U.S. FDA has granted priority review to a Kerendia application for patients with Type-1 diabetes and chronic kidney disease, broadening the drug's reach on two continents simultaneously.

Next week, all eyes will be on the American Society of Clinical Oncology (ASCO) congress in Chicago starting May 29. Bayer is set to present sixteen abstracts from its oncology pipeline, headlined by primary data from the phase II ARACOG trial. The study pits Nubeqa (darolutamide) directly against enzalutamide in prostate cancer, and positive head-to-head results would strengthen the drug's market position. Additional data on Xofigo and Vitrakvi are also expected.

Solid First Quarter Backs Guidance

Bayer's core earnings per share for the first quarter of 2026 climbed to €2.71 from €2.40 a year earlier, and management confirmed its full-year forecast on a currency-adjusted basis. Analysts have taken note: DZ Bank upgraded the stock to "Buy" on May 19 with a fair value of €51.00, while the consensus price target stands near €44.00—implying about 14% upside from current levels.

Technically, the shares are trading just below their 50-day moving average of €38.88 but well above the 200-day line of €35.44. The ASCO readout later this week will test whether the recent rally has real momentum behind it.

Supreme Court Decision Could Reshape Legal Landscape

Beyond the Missouri skirmish, a more consequential legal event is on the horizon. By the end of June, the U.S. Supreme Court is expected to rule in the Durnell case, which asks whether state-law failure-to-warn claims are preempted by federal law. A ruling in Bayer's favour would undercut the legal basis for thousands of pending Roundup lawsuits, radically altering the risk profile the stock has been wrestling with for years. Until that decision lands, Bayer will continue to navigate a dual narrative of promising pipeline catalysts and persistent legal storm clouds.